Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Co-Development with CellGenTech of a Regenerative Medicine Product for Fabry Disease

First written in FY2023-Q1. . Latest entry: FY2023-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint development of a regenerative medicine product for Fabry disease with セルジェンテックA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023-Q1First statedAnnual report

    「In May 2022, KYORIN Pharmaceutical Co.,Ltd. entered into a “Co-Development and License Agreement” with CellGenTech Co., Ltd. for a regenerative medicine product using genetically modified human adipocytes to treat Fabry disease, thereby acquiring a development product for rare and intractable diseases identified in its business strategy.」

    Under the agreement with CellGenTech, the Group acquired co-development rights and other rights for a regenerative medicine product using genetically modified human adipocytes to treat Fabry disease.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Co-Development with CellGenTech of a Regenerative Medicine Product for Fabry Disease | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori